TickerFacts.

Alpha Teknova, Inc. (TKNO): Gross Profit

Annual figures by period end, from SEC filings.

$13.44M
Year ended 2025-12-31
$15.12M
Trailing 12 months to 2026-06-30
-8.4%
3-year compound annual growth
-5.4%
5-year compound annual growth
$17.75M2020-12-31: $17.75M2021-12-31: $17.62M2022-12-31: $17.48M2023-12-31: $10.30M2024-12-31: $7.23M2025-12-31: $13.44M$13.44M
2020-12-31 Gross Profit (USD) 2025-12-31
Period endedGross ProfitChange YoYSource filing
2025-12-31$13.44M+85.9%2026-03-02, From 2025-01-01
2024-12-31$7.23M-29.8%2026-03-02, From 2024-01-01
2023-12-31$10.30M-41.1%2025-03-07, From 2023-01-01
2022-12-31$17.48M-0.8%2024-03-27, From 2022-01-01
2021-12-31$17.62M-0.8%2023-03-30, From 2021-01-01
2020-12-31$17.75Mn/a2022-03-18, From 2020-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedGross ProfitChange YoY
Alpha Teknova, Inc. (TKNO)2025-12-31$13.44M+85.9%
Immucell Corp (ICCC)2025-12-31$11.45M+44.1%
Aspira Women's Health Inc. (AWHL)2025-12-31$5.92M+8.0%
Anbio Biotechnology (NNNN)2025-12-31$7.54M+28.2%
Biomerica Inc (BMRA)2026-05-31$362.0K-27.3%
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31$2.30M+210.5%
Myriad Genetics Inc (MYGN)2025-12-31$576.60M-1.5%
Neogen Corp (NEOG)2026-05-31$408.50M-3.1%
Celldex Therapeutics, Inc. (CLDX)2025-12-31$1.34Mn/a

Compare TKNO, ICCC, AWHL, NNNN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗